Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Pediatric Participants With Prurigo Nodularis
NCT06293053Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- May 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in prurigo nodularis (PN), sponsored by Sanofi. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06293053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293053.